Edition:
United Kingdom

Profile: BioCryst Pharmaceuticals Inc (BCRX.OQ)

BCRX.OQ on NASDAQ Stock Exchange Global Select Market

2.50USD
23 Aug 2019
Change (% chg)

$-0.07 (-2.72%)
Prev Close
$2.57
Open
$2.56
Day's High
$2.68
Day's Low
$2.49
Volume
421,760
Avg. Vol
551,667
52-wk High
$9.94
52-wk Low
$2.49

BioCryst Pharmaceuticals, Inc., incorporated on November 15, 1991, is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine.

The Company's product RAPIVAB contains peramivir. Peramivir is an intravenous neuraminidase inhibitor approved in various countries for the treatment of patients with influenza. Peramivir is available commercially in the United States and has been approved for commercial use in Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU. Peramivir is used for the treatment of acute uncomplicated influenza in patients of approximately 18 years and older who have been symptomatic for over two days. Avoralstat is a drug candidate as an oral prophylactic treatment for HAE. BCX7353 targets plasma kallikrein. It has initiated a Phase I clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX7353 in healthy volunteers. ALPIVAB is an intravenous neuraminidase inhibitor.

Galidesivir is a broad-spectrum antiviral (BSAV) research program and is being developed under contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (BARDA/HHS) and the National Institute of Allergy and Infectious Diseases (NIAID/HHS). The primary focus of the program is treatment of hemorrhagic fever viruses. Galidesivir has been shown to be active against more than 20 ribonucleic acid (RNA) viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer under a world-wide license agreement. PNP is a purine salvage pathway enzyme. High doses of PNP inhibitors could be useful in the treatment of hematological malignancies. Mundipharma has received orphan drug status for forodesine, and has filed a Japanese New Drug Application (JNDA) with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).

The Company competes with F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Daiichi Sankyo Co., Ltd., FUJIFIM Corporation, Tekmira Pharmaceuticals Corporation and Mapp Biopharmaceutical, Inc.

Company Address

BioCryst Pharmaceuticals Inc

4505 Emperor Blvd Ste 200
DURHAM   NC   27703-8457
P: +1919.8591302
F: +1919.8591314

Company Web Links